CVS Health stock trades at USD 87.60 as guidance rises

Published on 09/22/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock closed at USD 87.60 on September 21, 2026, down 1.4 percent. Full-year guidance now targets USD 7.90 to USD 8.10 EPS.

Schwarzweiß-Reportagefoto eines Apothekers beim Befüllen von Rezeptmedikamenten an der Theke — CVS Health Corp. dokumentiert Schwarzweiß-Reportage eines Apothekers bei der Rezeptabgabe, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (ISIN US1266501006) closed at USD 87.60 on the New York Stock Exchange on September 21, 2026, down 1.4 percent from the prior session. The immediate investor signal is valuation against upgraded company guidance: 2026 adjusted earnings are now projected at USD 7.90 to USD 8.10 per share.

Guidance moves above the prior range

According to Yahoo Finance on September 21, 2026, CVS lifted its 2026 revenue projection to at least USD 414 billion from at least USD 405 billion. The increase represents a USD 9 billion improvement in the stated revenue floor.

The same report says adjusted earnings guidance rose from USD 7.30 to USD 7.50 per share to USD 7.90 to USD 8.10. The lower end therefore increased by USD 0.60, while the upper end increased by USD 0.60, giving the market a concrete measure of the revision.

Price remains below consensus value

CVS closed at USD 87.60 on September 21, 2026, while the latest quoted Street target in TIKR's September 22, 2026 analysis is USD 116.28. That target is USD 28.68 above the closing price, a difference of 32.74 percent calculated from the two stated values.

According to TIKR on September 22, 2026, the analyst distribution comprised 18 Buy ratings, 7 Outperform ratings and 3 Holds, with no Sell ratings. The mean target of USD 116.28 contrasts with the stock's forward price-to-earnings ratio of 10.94 in the same analysis.

Revenue growth sets the next test

Yahoo Finance reported on September 21, 2026, that the current quarterly revenue consensus was USD 105.04 billion, representing growth of 2.11 percent from the year-earlier quarter. Full-year consensus called for USD 418.17 billion in revenue and USD 8.02 in earnings per share, placing the guidance range around that earnings estimate.

The comparison matters because the upgraded revenue floor of USD 414 billion remains USD 4.17 billion below the cited full-year consensus of USD 418.17 billion. CVS therefore enters the next reporting checkpoint with higher company guidance, but the market's published revenue estimate still sits above the minimum outlook figure.

CVS stock closes at USD 87.60

CVS Health stock closed at USD 87.60 on the New York Stock Exchange on September 21, 2026, with a daily decline of 1.4 percent. The price, the USD 414 billion revenue floor and the USD 7.90 to USD 8.10 adjusted earnings range frame the current valuation discussion.